USC Comparison Study of Leading Targeted Therapies for ALK+ Lung Cancer Could Lead to Better Treatment Decisions
May 20, 2026
May 20, 2026
LOS ANGELES, California, May 20 (TNSjou) -- The University of Southern California Keck School of Medicine issued the following news release:
* * *
USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions
In the largest real-world analysis of U.S. patients, researchers used insurance claims data to study the effectiveness of five drugs known as tyrosine kinase inhibitors to better understand differences . . .
* * *
USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions
In the largest real-world analysis of U.S. patients, researchers used insurance claims data to study the effectiveness of five drugs known as tyrosine kinase inhibitors to better understand differences . . .